---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-270384"
form_type: "8-K"
ticker: "ENGN"
cik: "0001980845"
company_name: "enGene Therapeutics Inc."
filed_at: "2026-06-15T13:14:40+00:00"
generated_at: "2026-06-15T13:15:10.898999+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# enGene cuts workforce ~50%, CMO and CFO resign; Q2 loss widens to $30.2M

## Summary
- Workforce reduction of ~50% to streamline ops and preserve cash; restructuring costs est. $5.7-$6.4M cash plus $4.7-$5.0M non-cash stock comp.
- CFO Ryan Daws to depart July 15, 2026; Kathleen Richton appointed SVP Finance and principal financial officer.
- CMO Dr. Hussein Sweiti resigned effective June 14; Dr. William Grossman named interim CMO.
- Q2 net loss $30.2M ($0.43/share) vs $25.8M ($0.51/share) YoY; cash, equivalents and marketable securities $285.2M.
- LEGEND Cohort 1: 54% CR at any time; awaiting 12-month durability data; BLA filing and FDA meeting planned for 2H 2026.

## SEC filing metadata
- accession: 0001193125-26-270384
- form_type: 8-K
- ticker: ENGN
- cik: 0001980845
- company_name: enGene Therapeutics Inc.
- filed_at: 2026-06-15T13:14:40+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 2.05, 5.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1980845/000119312526270384/0001193125-26-270384-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1980845/000119312526270384/engn-20260613.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-270384
- JSON: https://secwatch.observer/filing/0001193125-26-270384.json
- Plain text: https://secwatch.observer/filing/0001193125-26-270384.txt

## Key facts
- Earnings Releases
  enGene Therapeutics Inc. reported financial results for the second quarter ended April 30, 2026.
  - Period: the second quarter ended April 30, 2026
  - Result: reported results
  source text: enGene Therapeutics Inc. (the “Company”) announced its financial results for the three months ended April 30, 2026
  evidence_url: https://www.sec.gov/Archives/edgar/data/1980845/000119312526270384/0001193125-26-270384-index.htm
- Executive change
  Hussein Sweiti resigned as Chief Medical Officer at enGene Therapeutics Inc..
  - Action: resigned
  - Role: Chief Medical Officer
  source text: On June 13, 2026, Dr. Hussein Sweiti notified the Company of his resignation from his position as Chief Medical Officer and Head of Research and Development of the Company, with his resignation to be effective as of June 14, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1980845/000119312526270384/0001193125-26-270384-index.htm
- Executive change
  Kathleen Richton was appointed as Senior Vice President, Finance at enGene Therapeutics Inc..
  - Action: appointed
  - Role: Senior Vice President, Finance
  source text: the Board appointed Kathleen Richton as Senior Vice President, Finance of the Company, with her appointment to become effective on or about July 16, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1980845/000119312526270384/0001193125-26-270384-index.htm
- Executive change
  Ryan Daws departed as Chief Financial Officer at enGene Therapeutics Inc..
  - Action: depart
  - Role: Chief Financial Officer
  source text: the Company announced that its Chief Financial Officer, Ryan Daws, will depart the Company effective July 15, 2026
  evidence_url: https://www.sec.gov/Archives/edgar/data/1980845/000119312526270384/0001193125-26-270384-index.htm
- Restructurings & Charges
  enGene Therapeutics Inc. announced a restructuring with charges of approximately $5.7 to $6.4 million affecting the Company (approximately 50%).
  - Type: restructuring
  - Charge: approximately $5.7 to $6.4 million
  - Affected area: the Company
  - Headcount: approximately 50%
  source text: activities required to support the commercial launch of detalimogene in 2027, if approved. The Company currently estimates it will incur restructuring costs of approximately $5.7 to $6.4 million, consisting primarily of employee severance, benefits, and other related costs, as well as approximately $4.7 million to $5.0 million in non-cash stock-based
  evidence_url: https://www.sec.gov/Archives/edgar/data/1980845/000119312526270384/0001193125-26-270384-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.